Sample 10

Evaluation Instructions

Important: Models were tasked with extracting evidence from documents. Some outputs may be low quality and should be scored accordingly.

Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).

Clean view: Shows formatted, readable text for easy comparison
Diff view: Highlights differences between ground truth and prediction
Raw view: Shows original unformatted text as it appears in the dataset

Evaluation scale (0-4):

0 = No match: Prediction is unrelated or contradicts the target criteria
1 = Poor match: Minimal overlap with ground truth, major errors or omissions
2 = Partial match: Some key elements captured, but notable gaps or inaccuracies
3 = Good match: Most elements correct, minor differences or formatting issues
4 = Excellent match: Essentially identical content, fully correct capture

Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.

Ground Truth

INCLUSION CRITERIA

  1. Plasma HIV-1 RNA ≥ 500 copies/mL at screening Visit
  2. Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTINo prior or current ARV regimens containing integrase inhibitor (INSTI) or protease inhibitor (PI)
  3. Screening genotype must show at least the protocol defined resistance mutation profile

EXCLUSION CRITERIA

  1. Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1
  2. Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial
  3. Use of an investigational drug other than the study drug
  4. Individuals with chronic hepatitis B virus (HBV) infection are not permitted to participate
  5. Active tuberculosis infectionNOTE: Other protocol defined Inclusion/

EXCLUSION CRITERIA

  1. may apply.

Prediction

Amended Eligibility Criteria for Version 15 of the Clinical Trial

INCLUSION CRITERIA

1. Plasma HIV-1 RNA ≥ 500 copies/mL at Screening Visit: This is a key inclusion criterion, reflecting the study's focus on patients with a high viral load.
2. Currently taking a failing antiretroviral (ARV) regimen that contains 2 NRTIs and a non-NRTI (NNRTI): This criterion ensures the study population is comprised of patients who have not responded adequately to current ARV therapy.
3. No prior or current ARV regimens containing integrase inhibitors (INSTI) or protease inhibitors (PI): This criterion excludes patients who have previously received these classes of ARVs, as they may have different pharmacokinetic profiles and potential interactions with the study drug.
4. No prior or current active infections requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1: This criterion ensures the study is conducted in a safe environment for patients with active infections.
5. Not currently participating in any other clinical trial, including observational studies, without prior approval from the sponsor: This criterion ensures the study is not overly burdened by concurrent clinical trials.
6. Use of investigational drug other than the study drug: This criterion ensures the study drug is the primary treatment and not a secondary intervention.
7. Individuals with chronic hepatitis B virus (HBV) infection are not permitted to participate: This criterion excludes patients with HBV infection, as it may interfere with the study drug's efficacy.

EXCLUSION CRITERIA

1. Active tuberculosis infection: This criterion ensures the study is conducted in a safe environment for patients with active tuberculosis.
2. Other significant medical conditions that may interfere with the study: This criterion ensures the study is conducted in a safe environment for patients with other medical conditions.
3. Note:** This is a summary of the amended eligibility criteria. The full document should be reviewed for a complete understanding of the criteria.